TY - JOUR
T1 - Antibody profiling of kawasaki disease using Escherichia coli proteome microarrays
AU - Kuo, Ho Chang
AU - Huang, Ying Hsien
AU - Chung, Feng Hsiang
AU - Chen, Po Chung
AU - Sung, Tzu Cheng
AU - Chen, Yi Wen
AU - Hsieh, Kai Sheng
AU - Chen, Chien Sheng
AU - Syu, Guan Da
N1 - Funding Information:
* This study was supported by grants from the Ministry of Science and Technology, Taiwan (MOST 105-2314-B-182-050-MY3, MOST 104-2320-B-008-002-MY3, and MOST 104-2627-M-008-001), the Aim for the Top University Project (104G705-4), the Ministry of Health and Welfare (PMRPG8E0011) and the Chang Gung Memorial Hospital (CMRPG8C1082, CMRPG8B0212, CMRPG8D1562, CORPG8F0011, CMRPG8E1611, and CMRPG8D0521 to HC-K) of Taiwan. □S This article contains supplemental material. ** To whom correspondence should be addressed: Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Edward D. Miller Research Building, 733 N. Broadway, Baltimore, MD 21205, Tel: 410-502-2807; Fax: 410-502-1872; E-mail: [email protected] or Graduate Institute of Systems Biology and Bioin-formatics Department of Biomedical Science and Engineering National Central University No. 300, Rd. Zhongda, Dist. Zhongli Taoyuan City 32001, Taiwan, ROC. Tel.: 886-3-4227151 ext. 36103; Fax: 886-3-4253427; E-mail: [email protected].
Publisher Copyright:
© 2018 by The American Society for Biochemistry and Molecular Biology, Inc.
PY - 2018/3
Y1 - 2018/3
N2 - Kawasaki disease (KD) is a form of systemic vasculitis that generally occurs in children under 5 years old. Currently, KD is still diagnosed according to its clinical symptoms, including prolonged fever, skin rash, conjunctivitis, neck lymphadenopathy, palm erythema, and oral mucosa changes. Because KD is a type of inflammation without specific marker for diagnosis, we plan to profile the plasma antibodies by using E. coli proteome microarray and analyze the differences between KD and healthy subjects. Plasmas were collected from KD patient before intravenous immunoglobulin treatment (KD1), at least 3 weeks after treatment (KD3), nonfever control (NC), and fever control (FC) children. The initial screening, which consisted of 20 KD1, 20 KD3, 20 NC, and 20 FC, were explored using E. coli proteome microarrays (-4200 unique proteins). About-70 proteins were shown to have high accuracy, e.g. 0.78-0.92, with regard to separating KD1, KD3, NC, and FC. Those proteins were then purified to fabricate KD focus arrays for training (n-20 each) and blind-testing (n-20 each). It only took 125 pl of plasma, less than a drop of blood, in the focus array assays. The AUC scores for blind tests of KD1 versus NC (17 protein markers), KD1 versus FC (20 protein markers), KD3 versus NC (9 protein markers), and KD1 versus KD3 (6 protein markers) were 0.84, 0.75, 0.99 and 0.98, respectively. This study is the first to profile plasma antibodies in KD and demonstrate that an E. coli proteome microarray can screen differences among patients with KD, nonfever controls, and fever controls.
AB - Kawasaki disease (KD) is a form of systemic vasculitis that generally occurs in children under 5 years old. Currently, KD is still diagnosed according to its clinical symptoms, including prolonged fever, skin rash, conjunctivitis, neck lymphadenopathy, palm erythema, and oral mucosa changes. Because KD is a type of inflammation without specific marker for diagnosis, we plan to profile the plasma antibodies by using E. coli proteome microarray and analyze the differences between KD and healthy subjects. Plasmas were collected from KD patient before intravenous immunoglobulin treatment (KD1), at least 3 weeks after treatment (KD3), nonfever control (NC), and fever control (FC) children. The initial screening, which consisted of 20 KD1, 20 KD3, 20 NC, and 20 FC, were explored using E. coli proteome microarrays (-4200 unique proteins). About-70 proteins were shown to have high accuracy, e.g. 0.78-0.92, with regard to separating KD1, KD3, NC, and FC. Those proteins were then purified to fabricate KD focus arrays for training (n-20 each) and blind-testing (n-20 each). It only took 125 pl of plasma, less than a drop of blood, in the focus array assays. The AUC scores for blind tests of KD1 versus NC (17 protein markers), KD1 versus FC (20 protein markers), KD3 versus NC (9 protein markers), and KD1 versus KD3 (6 protein markers) were 0.84, 0.75, 0.99 and 0.98, respectively. This study is the first to profile plasma antibodies in KD and demonstrate that an E. coli proteome microarray can screen differences among patients with KD, nonfever controls, and fever controls.
UR - http://www.scopus.com/inward/record.url?scp=85042671980&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042671980&partnerID=8YFLogxK
U2 - 10.1074/mcp.RA117.000198
DO - 10.1074/mcp.RA117.000198
M3 - Article
C2 - 29246958
AN - SCOPUS:85042671980
SN - 1535-9476
VL - 17
SP - 472
EP - 481
JO - Molecular and Cellular Proteomics
JF - Molecular and Cellular Proteomics
IS - 3
ER -